Stay updated on Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.

Latest updates to the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check38 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check45 days agoChange DetectedRevision: v3.4.3 is now displayed, replacing Revision: v3.4.2.SummaryDifference0.1%

- Check52 days agoChange DetectedThe two screenshots show only layout/UI adjustments with no changes to the study details or key data.SummaryDifference0.0%

- Check59 days agoChange Detected- No substantive content changes detected; core study information remains the same, with only layout and visual adjustments visible in the screenshots.SummaryDifference0.0%

- Check66 days agoChange DetectedFallopian tube cancer was added to the study conditions, and the Genetic and Rare Diseases Information Center resource was added.SummaryDifference0.1%

Stay in the know with updates to Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.